arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Rhythm Pharmaceuticals, Inc.

RYTM Health Care Biotechnology: Pharmaceutical Preparations
$102.74
Today
as of Sep 4, 16:54 ET
Last 30 days -4.91% Jul 28 → Sep 04
$97.78 $103.10 $108.42 $113.75 $119.07 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$103.53
High
$105.71
Low
$101.25
Volume
$466,903
Avg Vol
$750,214
Mkt Cap
$8.0B
P/E (TTM)
—
Beta
—
52w High
$122.20
52w Low
$74.50
Div Yield
—
Shares Out
$69M

Recent Press Releases & News last 60 days · 23 items

Aug 28 · 11:26 MT Newswires
Deutsche Bank Initiates Rhythm Pharmaceuticals at Hold With $120 Price Target
Aug 26 · 10:15 Simply Wall St.
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run
Aug 24 · 12:43 MT Newswires
Rhythm Pharmaceuticals Receives Japan Approval for Imcivree
▸ Show all 23 press releases & news Free account →

Overview

52-week range
$74
$122
59% of range
Avg surprise (last 3)
-9.2%
Avg reaction (last 2)
+5.5%
100% positive
Latest IV / EM
43%
EM ±6.7% · $105 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.35$-1.90$-1.45$-1.00$-0.55 Actual $-0.92Actual $-0.82Actual $-0.76Actual $-2.35Actual $-0.55Actual $-0.73Actual $-0.81Est $-0.69Actual $-0.75Est $-0.66Actual $-0.82Actual $-0.83Est $-0.86Actual $-0.73 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-56M$-23M$10M$42M$75M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.73 — — — — financials
Tue May 5, 2026Mar/2026 $-0.83 $-0.86 +3.5% -2.5% +7.9% earnings
Tue Sep 30, 2025Sep 2025 $-0.82 — — — — financials
Tue Aug 5, 2025Jun/2025 $-0.75 $-0.66 -13.6% — — earnings
Wed May 7, 2025Mar/2025 $-0.81 $-0.69 -17.4% — +3.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.73 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.55 — — — — financials
Sun Mar 31, 2024Mar 2024 $-2.35 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.76 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.82 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.92 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$71M$60M—$51M$49M$33M—$33M
Cost of revenue$9M$7M—$5M$6M$4M—$4M
Gross profit————————
Operating income$-49M$-52M—$-53M$-45M$-47M—$-44M
Net income$-49M$-56M—$-53M$-47M$-49M—$-44M
EPS (diluted)$-0.73$-0.83—$-0.82$-0.75$-0.81—$-0.73

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$66M$62M$54M$52M$136M$106M$89M$48M
Inventory$31M$29M$26M$22M$19M$19M$19M$14M
Total current assets$427M$430M$467M$495M$361M$369M$374M$340M
Total assets$437M$442M$480M$507M$373M$387M$392M$364M
Long-term debt$93M$98M$101M$103M$106M$108M$108M—
Total liabilities$220M$205M$210M$211M$239M$224M$228M$211M
Total equity$103M$123M$139M$149M$-12M$19M$22M$11M

Implied volatility — last 90 days

43%69%95%121%147% Jun 07 — IV 112% · EM ±15.5%Jun 08 — IV 115% · EM ±15.2%Jun 09 — IV 122% · EM ±15.3%Jun 10 — IV 148% · EM ±17.4%Jun 11 — IV 129% · EM ±14.3%Jun 12 — IV 128% · EM ±13.1%Jun 15 — IV 76% · EM ±5.5%Jun 16 — IV 93% · EM ±5.5%Jun 17 — IV 94% · EM ±3.9%Jun 19 — IV 47% · EM ±10.4%Jun 22 — IV 53% · EM ±11.1%Jun 23 — IV 54% · EM ±11.1%Jun 24 — IV 55% · EM ±11.1%Jun 25 — IV 54% · EM ±10.6%Jun 26 — IV 56% · EM ±10.7%Jun 29 — IV 54% · EM ±9.6%Jun 30 — IV 48% · EM ±8.2%Jul 01 — IV 55% · EM ±9.2%Jul 02 — IV 54% · EM ±8.7%Jul 03 — IV 56% · EM ±8.8%Jul 06 — IV 61% · EM ±8.4%Jul 07 — IV 61% · EM ±8.1%Jul 08 — IV 57% · EM ±7.1%Jul 09 — IV 58% · EM ±6.8%Jul 10 — IV 62% · EM ±6.8%Jul 13 — IV 75% · EM ±6.3%Jul 14 — IV 73% · EM ±5.3%Jul 15 — IV 77% · EM ±4.5%Jul 16 — IV 103% · EM ±4.3%Jul 20 — IV 69% · EM ±16.3%Jul 21 — IV 67% · EM ±15.6%Jul 22 — IV 67% · EM ±15.3%Jul 23 — IV 66% · EM ±14.9%Jul 24 — IV 64% · EM ±14.2%Jul 27 — IV 70% · EM ±14.6%Jul 28 — IV 69% · EM ±14.2%Jul 29 — IV 71% · EM ±14.3%Jul 30 — IV 69% · EM ±13.5%Jul 31 — IV 72% · EM ±13.8%Aug 03 — IV 76% · EM ±13.4%Aug 04 — IV 49% · EM ±8.4%Aug 05 — IV 53% · EM ±8.8%Aug 06 — IV 51% · EM ±8.2%Aug 07 — IV 52% · EM ±8.2%Aug 10 — IV 59% · EM ±8.1%Aug 11 — IV 54% · EM ±7.1%Aug 12 — IV 50% · EM ±6.3%Aug 13 — IV 52% · EM ±6.1%Aug 14 — IV 50% · EM ±5.5%Aug 17 — IV 66% · EM ±5.5%Aug 18 — IV 52% · EM ±3.8%Aug 19 — IV 75% · EM ±4.4%Aug 20 — IV 84% · EM ±3.5%Aug 24 — IV 48% · EM ±10.0%Aug 25 — IV 50% · EM ±10.2%Aug 26 — IV 48% · EM ±9.7%Aug 27 — IV 46% · EM ±9.0%Aug 28 — IV 46% · EM ±8.9%Aug 31 — IV 49% · EM ±8.7%Sep 01 — IV 49% · EM ±8.5%Sep 02 — IV 46% · EM ±7.7%Sep 03 — IV 47% · EM ±7.7%Sep 04 — IV 43% · EM ±6.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in